Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1

BACKGROUND: A newly developed drug trastuzumab emtansine (T-DM1) has improved the survival of breast cancer (BC) patients. Despite an impressive initial clinical response, a subgroup of patient develop resistance and present therapeutic challenges. The underlying resistance mechanisms are not fully...

Descripción completa

Detalles Bibliográficos
Autores principales: Islam, Syed S., Uddin, Mohammed, Noman, Abu Shadat M., Akter, Hosneara, Dity, Nusrat J., Basiruzzman, Mohammad, Uddin, Furkan, Ahsan, Jahanara, Annoor, Sunera, Alaiya, Ayodele A., Al-Alwan, Monther, Yeger, Herman, Farhat, Walid A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558306/
https://www.ncbi.nlm.nih.gov/pubmed/31085100
http://dx.doi.org/10.1016/j.ebiom.2019.04.061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558306/
https://www.ncbi.nlm.nih.gov/pubmed/31085100
http://dx.doi.org/10.1016/j.ebiom.2019.04.061

Ejemplares similares